What is HC Wainwright's Estimate for SNDX Q3 Earnings?

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Syndax Pharmaceuticals to a loss of $0.53 per share from a previous loss estimate of $0.48, while maintaining a “Buy” rating.
• The firm forecasts Syndax will remain unprofitable through 2027, with projected EPS of negative $2.07 for FY2026 and negative $0.79 for FY2027, before turning positive in 2028.
• Syndax’s latest quarterly results missed expectations, reporting a $0.55-per-share loss versus the $0.45 consensus estimate, though revenue rose 91.8% year over year to $72.79 million.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Stock analysts at HC Wainwright lowered their Q3 2026 earnings estimates for Syndax Pharmaceuticals in a report issued on Thursday, October 1st. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.53) for the quarter, down from their prior forecast of ($0.48). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals' Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.07) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at $0.10 EPS, FY2029 earnings at $1.53 EPS and FY2030 earnings at $2.39 EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.10). The business had revenue of $72.79 million during the quarter, compared to analyst estimates of $79.36 million. Syndax Pharmaceuticals had a negative return on equity of 372.94% and a negative net margin of 87.52%.The company's revenue was up 91.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.83) EPS.

Several other brokerages also recently issued reports on SNDX. Weiss Ratings upgraded Syndax Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday. UBS Group reaffirmed a "buy" rating on shares of Syndax Pharmaceuticals in a report on Thursday. JPMorgan Chase & Co. lowered their target price on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, September 29th. Finally, Bank of America reiterated a "buy" rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $41.80.

Syndax Pharmaceuticals Price Performance

SNDX stock opened at $17.60 on Monday. Syndax Pharmaceuticals has a twelve month low of $12.99 and a twelve month high of $25.59. The company has a quick ratio of 6.44, a current ratio of 6.77 and a debt-to-equity ratio of 38.95. The stock's 50 day moving average is $19.27 and its 200-day moving average is $20.76. The firm has a market capitalization of $1.56 billion, a PE ratio of -7.01 and a beta of 0.42.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. WINTON GROUP Ltd increased its position in Syndax Pharmaceuticals by 642.7% in the second quarter. WINTON GROUP Ltd now owns 76,500 shares of the company's stock worth $1,672,000 after buying an additional 66,200 shares during the last quarter. Jupiter Topco LLC purchased a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at $860,000. Orbimed Advisors LLC bought a new position in shares of Syndax Pharmaceuticals during the 1st quarter worth $22,479,000. Hennion & Walsh Asset Management Inc. grew its stake in shares of Syndax Pharmaceuticals by 59.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 342,883 shares of the company's stock worth $7,495,000 after acquiring an additional 128,076 shares during the period. Finally, Eventide Asset Management LLC increased its holdings in Syndax Pharmaceuticals by 25.3% in the 4th quarter. Eventide Asset Management LLC now owns 1,238,196 shares of the company's stock worth $26,014,000 after acquiring an additional 249,710 shares during the last quarter.

Insider Activity

In other news, CEO Michael Metzger sold 32,375 shares of Syndax Pharmaceuticals stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $24.24, for a total transaction of $784,770.00. Following the sale, the chief executive officer directly owned 484,843 shares in the company, valued at $11,752,594.32. The trade was a 6.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.80% of the stock is currently owned by corporate insiders.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company's research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax's lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.